| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Chris Fellne. Pharmaceutical Approval Update. P & T : a peer-reviewed journal for formulary management. vol 40. issue 12. 2015-12-18. PMID:26681901. |
idarucizumab (praxbind) to reverse the anticoagulant effects of dabigatran (pradaxa); aripiprazole lauroxil (aristada) for the treatment of schizophrenia; and insulin degludec injection (tresiba) for diabetes. |
2015-12-18 |
2023-08-13 |
Not clear |
| Francesco Franza, Vincenzo Fasano, Serena De Guglielmo, Barbara Solomit. Management of primary negative symptoms in schizophrenia: an one-year observational study. Psychiatria Danubina. vol 27 Suppl 1. 2015-12-17. PMID:26417773. |
in our study, we evaluated in an open-label study the efficacy of some second-generation antipsychotics (clozapine, quetiapine, olanzapine, aripiprazole, paliperidone) in 42 patients with schizophrenia or schizoaffective disorder (dsm-5 criteria) with 'persistent negative symptoms'. |
2015-12-17 |
2023-08-13 |
Not clear |
| Herbert Y Meltzer, Robert Risinger, Henry A Nasrallah, Yangchun Du, Jacqueline Zummo, Lisa Corey, Anjana Bose, Srdjan Stankovic, Bernard L Silverman, Elliot W Ehric. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. The Journal of clinical psychiatry. vol 76. issue 8. 2015-12-03. PMID:26114240. |
a randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. |
2015-12-03 |
2023-08-13 |
Not clear |
| Herbert Y Meltzer, Robert Risinger, Henry A Nasrallah, Yangchun Du, Jacqueline Zummo, Lisa Corey, Anjana Bose, Srdjan Stankovic, Bernard L Silverman, Elliot W Ehric. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. The Journal of clinical psychiatry. vol 76. issue 8. 2015-12-03. PMID:26114240. |
this study evaluated the efficacy, safety, and tolerability of aripiprazole lauroxil, a novel long-acting injectable atypical antipsychotic, for the treatment of schizophrenia. |
2015-12-03 |
2023-08-13 |
Not clear |
| John M Kane, Cathy Zhao, Brian R Johnson, Ross A Baker, Anna Eramo, Robert D McQuade, Anna R Duca, Raymond Sanchez, Timothy Peters-Stricklan. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. Journal of medical economics. vol 18. issue 2. 2015-11-25. PMID:25347448. |
to compare hospitalization rates in patients with schizophrenia treated prospectively with aripiprazole once-monthly 400 mg (aom 400; an extended-release injectable suspension) vs the same patients' retrospective rates with their prior oral anti-psychotic therapy. |
2015-11-25 |
2023-08-13 |
Not clear |
| Arash Raoufinia, Ross A Baker, Anna Eramo, Anna-Greta Nylander, Wally Landsberg, Dusan Kostic, Frank Larse. Initiation of aripiprazole once-monthly in patients with schizophrenia. Current medical research and opinion. vol 31. issue 3. 2015-11-06. PMID:25586294. |
initiation of aripiprazole once-monthly in patients with schizophrenia. |
2015-11-06 |
2023-08-13 |
Not clear |
| Guido Di Sciascio, Marco Andrea Riv. Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatric disease and treatment. vol 11. 2015-10-28. PMID:26508859. |
clinical experience with aripiprazole has confirmed the effectiveness and the safety of this novel antipsychotic drug in patients with schizophrenia as well as for the treatment of mania in type i bipolar disorder. |
2015-10-28 |
2023-08-13 |
Not clear |
| Leslie Citrome, Peter J Weiden, Gus Alva, Ira D Glick, Richard Jackson, Greg Mattingly, Farid Kianifard, Xiangyi Meng, Adam Winsec. Switching to iloperidone: An omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia. Clinical schizophrenia & related psychoses. vol 8. issue 4. 2015-10-19. PMID:25367165. |
to describe secondary analyses from a 12-week, randomized, open-label trial where adult schizophrenia outpatients receiving risperidone, olanzapine, or aripiprazole were switched to iloperidone. |
2015-10-19 |
2023-08-13 |
Not clear |
| Praveen Tripathi, Priyanka Goyal, Deepak Kumar, Om Prakas. High doses of aripiprazole therapy for a patient with treatment-resistant schizophrenia responsive to, but intolerant of, clozapine. The Australian and New Zealand journal of psychiatry. vol 49. issue 2. 2015-09-28. PMID:25217184. |
high doses of aripiprazole therapy for a patient with treatment-resistant schizophrenia responsive to, but intolerant of, clozapine. |
2015-09-28 |
2023-08-13 |
Not clear |
| Kazuto Oya, Taro Kishi, Nakao Iwat. Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Neuropsychiatric disease and treatment. vol 11. 2015-09-14. PMID:26366084. |
efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. |
2015-09-14 |
2023-08-13 |
Not clear |
| Kazuto Oya, Taro Kishi, Nakao Iwat. Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Neuropsychiatric disease and treatment. vol 11. 2015-09-14. PMID:26366084. |
we conducted a systematic review and meta-analysis of the efficacy of aripiprazole once monthly (aom) for schizophrenia. |
2015-09-14 |
2023-08-13 |
Not clear |
| Laura Alexandra Nussbaum, Victor Dumitraşcu, Anca Tudor, Raluca Grădinaru, Nicoleta Andreescu, Maria Pui. Molecular study of weight gain related to atypical antipsychotics: clinical implications of the CYP2D6 genotype. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie. vol 55. issue 3. 2015-08-25. PMID:25329115. |
our study, performed in 2009-2014, with a two-year enrolment period during which we recruited children and adolescents with a diagnosis of schizophrenia or bipolar disorder on treatment with the antipsychotics (risperidone, aripiprazole or olanzapine), included 81 patients, aged between 9 and 20 years, median age being 15.74 years. |
2015-08-25 |
2023-08-13 |
Not clear |
| W Wolfgang Fleischhacker, Raymond Sanchez, Pamela P Perry, Na Jin, Timothy Peters-Strickland, Brian R Johnson, Ross A Baker, Anna Eramo, Robert D McQuade, William H Carson, David Walling, John M Kan. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. The British journal of psychiatry : the journal of mental science. vol 205. issue 2. 2015-08-24. PMID:24925984. |
aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. |
2015-08-24 |
2023-08-13 |
Not clear |
| Ryan Turncliff, Marjie Hard, Yangchun Du, Robert Risinger, Elliot W Ehric. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. Schizophrenia research. vol 159. issue 2-3. 2015-08-19. PMID:25266547. |
relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. |
2015-08-19 |
2023-08-13 |
human |
| Ryan Turncliff, Marjie Hard, Yangchun Du, Robert Risinger, Elliot W Ehric. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. Schizophrenia research. vol 159. issue 2-3. 2015-08-19. PMID:25266547. |
this multicenter, randomized, open-label study evaluated the pharmacokinetics (pk), relative bioavailability, and tolerability of a single im deltoid or gluteal injection of aripiprazole lauroxil in adult subjects with chronic stable schizophrenia or schizoaffective disorder. |
2015-08-19 |
2023-08-13 |
human |
| Saeed Shoja Shafti, Hamid Kavian. Quetiapine versus aripiprazole in the management of schizophrenia. Therapeutic advances in psychopharmacology. vol 5. issue 3. 2015-07-22. PMID:26199719. |
quetiapine versus aripiprazole in the management of schizophrenia. |
2015-07-22 |
2023-08-13 |
Not clear |
| Saeed Shoja Shafti, Hamid Kavian. Quetiapine versus aripiprazole in the management of schizophrenia. Therapeutic advances in psychopharmacology. vol 5. issue 3. 2015-07-22. PMID:26199719. |
this article reviews the efficacy and tolerability of aripiprazole versus quetiapine in the context of recommended management strategies for schizophrenia. |
2015-07-22 |
2023-08-13 |
Not clear |
| Akifumi Nakamura, Kazuo Mihara, Kenji Nemoto, Goyo Nagai, Shoko Kagawa, Takeshi Suzuki, Tsuyoshi Kond. Lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in Japanese patients with schizophrenia. Therapeutic drug monitoring. vol 36. issue 6. 2015-07-20. PMID:24739668. |
lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in japanese patients with schizophrenia. |
2015-07-20 |
2023-08-13 |
Not clear |
| Kwang-Soo Baek, Shinbyoung Ahn, Jaehwi Lee, Ji Hye Kim, Han Gyung Kim, Eunji Kim, Jun Ho Kim, Nak Yoon Sung, Sungjae Yang, Mi Seon Kim, Sungyoul Hong, Jong-Hoon Kim, Jae Youl Ch. Immunotoxicological Effects of Aripiprazole: In vivo and In vitro Studies. The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology. vol 19. issue 4. 2015-07-14. PMID:26170741. |
aripiprazole (ari) is a commonly prescribed medication used to treat schizophrenia and bipolar disorder. |
2015-07-14 |
2023-08-13 |
Not clear |
| X Han, Y B Yuan, X Yu, J P Zhao, C Y Wang, Z Lu, F D Yang, H Dong, Y F Wu, G S Ungvari, Y T Xiang, H F K Chi. The Chinese First-Episode Schizophrenia Trial: background and study design. East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan. vol 24. issue 4. 2015-07-13. PMID:25482837. |
a total of 600 first-episode schizophrenia patients were randomly divided into 3 groups and treated with risperidone, aripiprazole, and olanzapine for 1 year. |
2015-07-13 |
2023-08-13 |
Not clear |